Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

Withdrawn

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: TAK-573
Drug: Bortezomib
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2020-05-19

Last Posted Date: 2020-07-14

Lead Sponsor: Takeda

Registration Number: NCT04392648

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Biological: N-803
Drug: 5-Fluorouracil
Drug: Aldoxorubicin HCl
Drug: Leucovorin
Procedure: SBRT
Biological: PD-L1 t-haNK
Drug: Irinotecan liposome
Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Cyclophosphamide

First Posted Date: 2020-05-15

Last Posted Date: 2024-10-18

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 328

Registration Number: NCT04390399

Locations: 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸
Hoag memorial Presbyterian Hospital, Newport Beach, California, United States

and more 1 locations

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

Phase 1

Withdrawn

Conditions: Ovarian Cancer Metastatic

Interventions: Drug: cyclophosphamide
Drug: fludarabine
Drug: IL-2 (Proleukin)
Genetic: Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)
Genetic: Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)

First Posted Date: 2020-05-15

Last Posted Date: 2020-12-16

Lead Sponsor: Immetacyte Ltd

Registration Number: NCT04389229

Locations: 🇬🇧
The Christies Hospital, Manchester, United Kingdom
🇬🇧
Queens Elizabeth Hospital, Birmingham, United Kingdom

Evolutionary Therapy for Rhabdomyosarcoma

Phase 2

Recruiting

Conditions: Rhabdomyosarcoma

Interventions: Drug: Vincristine
Drug: Cyclophosphamide
Drug: Vinorelbine
Drug: Actinomycin D
Drug: Cyclophosphamide Pill

First Posted Date: 2020-05-14

Last Posted Date: 2024-12-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 28

Registration Number: NCT04388839

Locations: 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States

and more 15 locations

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Secondary Myelofibrosis
Primary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Melphalan
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Magnetic Resonance Imaging
Procedure: Ultrasound Imaging

First Posted Date: 2020-05-12

Last Posted Date: 2024-10-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 45

Registration Number: NCT04384692

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

Early Phase 1

Recruiting

Conditions: Systemic Scleroderma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Total-Body Irradiation

First Posted Date: 2020-05-08

Last Posted Date: 2024-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT04380831

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1

Recruiting

Conditions: Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Undifferentiated Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Drug: Mycophenolate Sodium
Biological: Filgrastim
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone
Drug: Idarubicin
Drug: Mycophenolate Mofetil
Drug: Fludarabine
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography
Procedure: X-Ray Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2020-05-05

Last Posted Date: 2024-11-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT04375631

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: Cyclophosphamide
Drug: JAK Inhibitor
Drug: Fludarabine
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan

First Posted Date: 2020-04-30

Last Posted Date: 2024-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04370301

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2

Recruiting

Conditions: Autoimmune Lymphoproliferative
Common Variable Immunodeficiency
Immune System Diseases
Primary T-cell Immunodeficiency Disorders
Lymphoproliferative Disorders

Interventions: Drug: Busulfan test dose
Drug: Fludarabine
Drug: Busulfan
Drug: Alemtuzumab
Radiation: Total body Irradiation
Procedure: Allogeneic HSCT
Drug: Tacrolimus (Tacro)
Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide (Cytoxan)

First Posted Date: 2020-04-09

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT04339777

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Follicular Lymphoma
Ann Arbor Stage II Marginal Zone Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Follicular Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Parsaclisib
Biological: Pegfilgrastim
Drug: Polatuzumab Vedotin
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2020-03-27

Last Posted Date: 2023-10-30

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT04323956

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy